ARICEUM THERAPEUTICS
Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers. 177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, is an antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.
ARICEUM THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2021-01-01
Address:
Berlin, Berlin, Germany
Country:
Germany
Website Url:
http://www.ariceum-therapeutics.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
47.75 M EUR
Technology used in webpage:
Google Maps CrUX Dataset CrUX Top 10m
Similar Organizations
Cimeio Therapeutics
Cimeio Therapeutics develops curative treatments for genetic diseases, hematologic malignancies, and severe autoimmune disorders.
Rapt Therapeutics
Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.
Novasenta
Novasenta develops treatments to transform the lives of patients with cancer.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Sionna Therapeutics
Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF).
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Current Advisors List
Current Employees Featured
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2023-06-01 | Theragnostics | Theragnostics acquired by Ariceum Therapeutics | 41.5 M USD |
Investors List
Pureos Bioventures
Pureos Bioventures investment in Series A - Ariceum Therapeutics
Earlybird Venture Capital
Earlybird Venture Capital investment in Series A - Ariceum Therapeutics
Andera Partners
Andera Partners investment in Series A - Ariceum Therapeutics
Pureos Bioventures
Pureos Bioventures investment in Series A - Ariceum Therapeutics
HealthCap
HealthCap investment in Series A - Ariceum Therapeutics
EQT Life Sciences
EQT Life Sciences investment in Series A - Ariceum Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-07 | Ariceum Therapeutics Appoints Chief Business Officer |
Official Site Inspections
http://www.ariceum-therapeutics.com Semrush global rank: 5.45 M Semrush visits lastest month: 1.36 K
- Host name: 82.165.168.183
- IP address: 82.165.168.183
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Ariceum Therapeutics"
Ariceum Company Profile 2024: Valuation, Funding & Investors
Ariceum General Information Description. Operator of a biopharmaceutical company intended to develop targeted radiopharmaceuticals to visualize and treat cancer. The company focuses on …See details»
Ariceum Therapeutics GmbH - Drug pipelines, Patents, Clinical
Explore Ariceum Therapeutics GmbH with its drug pipeline, therapeutic area, technology platform, 5 clinical trials, 25 news, and 6 literature, Disease Domain:Neoplasms, Nervous System …See details»
Ariceum Therapeutics - Crunchbase Company Profile
Organization. Ariceum Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage …See details»
Ariceum Therapeutics announces opening of new state-of-the-art ...
Berlin, Germany, 5 March 2024 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to …See details»
Ariceum Therapeutics to present new radioligand therapy data at ...
Apr 4, 2024 /PRNewswire/ -- Ariceum Therapeutics ... (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent …See details»
Ariceum Therapeutics Presents Outstanding Data on its First-in …
Oct 22, 2024 Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, …See details»
Ariceum Therapeutics announces granting of US and Canadian …
BERLIN, Dec. 6, 2023 /PRNewswire/ -- Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to …See details»
Ariceum Therapeutics announces opening of new state-of-the-art ...
Mar 5, 2024 Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, …See details»
Ariceum Therapeutics Presents Outstanding Data on its First-in …
Berlin, Germany, 22 October 2024 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to …See details»
Ariceum Therapeutics announces granting of US and Canadian …
Dec 6, 2023 Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, is pleased to …See details»
Ariceum Therapeutics and AmbioPharm Enter Strategic …
Oct 27, 2022 Ariceum Therapeutics Manfred Rüdiger, CEO Email: [email protected] Optimum Strategic Communications Hollie Vile, Charlotte Hepburne-Scott, …See details»
Ariceum Therapeutics and AmbioPharm Enter Strategic …
Oct 27, 2022 BERLIN, Germany and NORTH AUGUSTA, S.C., USA, 27th October 2022 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical …See details»
Ariceum Therapeutics Appoints Chief Business Officer - PR Newswire
BERLIN, July 7, 2022 /PRNewswire/ -- Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted …See details»
About Us - Ariceum Therapeutics
Ariceum Therapeutics is a private company focused on developing novel targeted radiopharmaceuticals for the treatment of cancer Our lead targeted systemic …See details»
Ariceum Therapeutics and AmbioPharm Enter Strategic …
Oct 27, 2022 BERLIN, Germany and NORTH AUGUSTA, S.C., USA, 27 th October 2022 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical …See details»
Ariceum Therapeutics doses first patient with its first-in-class ...
BERLIN, Sept. 7, 2023 /PRNewswire/ -- Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain …See details»
EQT Life Sciences announces launch and series A Financing Round …
Jun 10, 2022 EQT Life Sciences announced that Ariceum Therapeutics (Ariceum), a private biotech company developing a radiopharmaceutical product for the diagnosis and targeted …See details»
Ariceum Therapeutics Presents Outstanding Data on its First-in …
BERLIN, Oct. 22, 2024 /PRNewswire/ -- Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain …See details»
Ariceum Therapeutics Launches with EUR 25M Series A to Advance …
Jun 8, 2022 Ariceum Therapeutics (Ariceum) is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and …See details»